Coya Therapeutics logo
Coya Therapeutics
COYA | NASDAQ
Chart Builder DCF Calculator
$3.00
-$0.13 (-4.15%)
At close: Nov 16, 2026, 4:00 PM ET
$2.96
-$0.04 (-1.33%)
After-hours: Nov 16, 2026, 7:30 PM ET

Coya Therapeutics Company Profile

Company profile explained

Company Profile

Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.

Key Executives

Name Position
Arun Swaminathan Chief Executive Officer & Director
David S. Snyder Chief Financial Officer & Chief Operating Officer
Aaron Thome Head of Neuroinflammation Platform
Fred Grossman FAPA President & Chief Medical Officer
Karen King Senior Vice President of Program Management & Clinical Operations
Michelle Frazier Senior Vice President of Regulatory

Latest SEC Filings

Date Type Title
Oct 14, 2026 8-K Current Report
Oct 05, 2026 8-K Current Report
Sep 15, 2026 8-K Current Report
Aug 11, 2026 10-Q Quarterly Report
Aug 11, 2026 8-K Current Report
Aug 07, 2026 8-K/A [Amend] Current Report
Jul 27, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Jun 25, 2026 8-K Current Report
May 13, 2026 ARS Filing
May 13, 2026 DEFA14A Filing
View All SEC Filings ➞
Coya Therapeutics
Coya Therapeutics logo
Country United States
IPO Date Dec 29, 2022
Industry Biotechnology
Sector Healthcare
Employees 8
CEO Arun Swaminathan

Contact Details

5850 San Felipe Street Houston, Texas 77057 United States

Stock Details

Ticker Symbol COYA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001835022
CUSIP Number 22407B108
ISIN Number US22407B1089
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.